MRNS - Marinus Bozor kapitallashuvining daromadga nisbati
Marinus Pharmaceuticals o'zining etik madaniyati va epilepsiya bilan kasallangan bemorlarga yordam berishga yo'naltirilganligi bilan olimlarni jalb qiladi. GURU.Markets platformasida narx-savdo koeffitsiyenti dinamikasini tahlil qilib, biz 1.00 ushbu metrikaning joriy qiymatini ifodalashini aniqladik. Kam uchraydigan kasalliklar dori vositasi maqomi kompaniyaga istisno darajadagi narx belgilash imkoniyatini beradi, garchi yakuniy daromad sug'urta jamg'armasi limitlari va patent himoyasiga bog'liq bo'lsa-da.
Marinus Pharmaceuticals (MRNS) kompaniyasi koʻrsatkichlari kesimi va tahlili
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi statistikasi:
- balans kapitallashuvi ko'rsatkichlari:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati Marinus Pharmaceuticals|MRNS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati marinuspharma.com|MRNS - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Marinus Pharma|MRNS - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari Marinus Pharmaceuticals|Tezkor likvidlik ko‘rsatkichi marinuspharma.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
MRNS - Sof foyda|Kutilayotgan sof foyda Marinus Pharmaceuticals|MRNS - Narx-foyda koeffitsiyenti|Forvard P/E multiplikatori Marinus Pharmaceuticals|MRNS - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati koeffitsiyenti Marinus Pharma|MRNS - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Marinus Pharmaceuticals|MRNS - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi 12 oy davomida bir aksiya uchun sof foydaning yillik o'sishi marinuspharma.com|MRNS - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Marinus Pharmaceuticals
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning fundamental tahlili:MRNS (Marinus Pharmaceuticals, Inc.)
Ushbu koeffitsient bozor kapitalizatsiyasining umumiy yillik daromadga nisbati sifatida hisoblanadi va aktivning baholash tuzilmasidagi daromad birligi qiymatini belgilaydi. Marinus Pharmaceuticals (MRNS) loyihalari oqimini saqlab qolishga qaratilgan xarajatlarni kamaytirish sharoitida, P/S koeffitsienti muvaffaqiyatsiz klinik sinovlardan keyingi boshqaruvni qayta tashkil etish fonida biznesning qadriyati past baholanganmi yoki haddan tashqari to'lov qilish xavfi mavjudmi, shuni baholash imkonini beradi.
Raqobatdosh kompaniyalar
BIIB (Biogen) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori NBIX (Neurocrine Corp)|Regencell Bioscience - Narxning daromadga nisbati|Axsome Therapeutics - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Narxning daromadga nisbati|Sotuvga nisbatan narx Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S multiplikatori|CPRX: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori DNLI|Narx/daromad koeffitsiyenti Harmony Biosciences|Biohaven Ltd - Kapitalizatsiyaning daromadga nisbati|P/S multiplikatori Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Kapitalizatsiyaning daromadga nisbati|Narx/daromad koeffitsiyenti Praxis Corp PRAX|AVXL: P/S multiplikatori|CBLL (ceribell.com) - Narxning daromadga nisbati|PRTA (Prothena Corporation) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati alector.com (ALEC)|Narxning daromadga nisbati Annexon, Inc. (ANNX)|OMER - Sotuvga nisbatan narx|P/S multiplikatori NGNE (Neurogene Inc)|AC Immune (ACIU) - Sotuvga nisbatan narx|Voyager Therapeutics Inc - P/S multiplikatori|Neumora (NMRA) - Kapitalizatsiyaning daromadga nisbati|SCLX: P/S multiplikatori|TVGN - Narx/daromad koeffitsiyenti|ACOG (Alpha Cognition Inc) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati cogrx.com (CGTX)|Narxning daromadga nisbati Inhibikase Therapeutics Inc (IKT)|Narx/daromad koeffitsiyenti Cassava Sciences|P/S multiplikatori ASRT (Assertio Holdings)|COYA - Kapitalizatsiyaning daromadga nisbati|vistagen.com - P/S multiplikatori|OVID: Narxning daromadga nisbati|Acumen Pharmaceuticals, Inc (ABOS) - Narxning daromadga nisbati|CervoMed Inc - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Alterity Therapeutics Limited|clene.com (CLNN) - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati PEPG (PepGen Inc)|P/S multiplikatori jupiterneurosciences.com (JUNS)|Narxning daromadga nisbati Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalizatsiya va daromad nisbati|Grace Tx - P/S multiplikatori|AIFF (Firefly Neuroscience Inc) - Kapitalizatsiya va daromad nisbati|KLTO: P/S multiplikatori|NeuroSense Therapeutics, Ltd. (NRSN) - P/S multiplikatori|Narxning daromadga nisbati Reviva Pharmaceuticals, Inc.|Kapitalizatsiyaning daromadga nisbati metaviatx.com (MTVA)|P/S multiplikatori NRXS|HSDT - Sotuvga nisbatan narx|Passage Bio, Inc. - Kapitalizatsiyaning daromadga nisbati|bionomics.com.au (NEUP) - Sotuvga nisbatan narx|Minerva - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati ATHA (Athira Pharma Inc)|ADXN: P/S multiplikatori|Kapitalizatsiya va daromad nisbati ALZN|CYCN (Cyclerion Therapeutics Inc.) - P/S multiplikatori|PTIX (Protagenic Therapeutics) - Kapitalizatsiyaning sotish hajmiga nisbati|P/S multiplikatori KTTA|Narx/daromad koeffitsiyenti Cortigent|P/S multiplikatori ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Narxning daromadga nisbati|Cara Therapeutics Inc. - P/S multiplikatori|Chromocell Therapeutics (CHRO) - Kapitalizatsiyaning daromadga nisbati|ELYM: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - P/S multiplikatori|NKGN: Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori NRBO|SAGE: Narxning sotuvga nisbati|Synaptogenix Inc. - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S multiplikatori|Anew Medical (WENA) - Kapitalizatsiyaning daromadga nisbati|CERE (Cerevel Corp) - Kapitalizatsiyaning daromadga nisbati
